Limited coverage criteria – leuprolide acetate (extended-release)
Last updated on May 6, 2026
Return to Special Authority drug list
Generic name |
leuprolide acetate |
|
Strength & form |
45 mg (6-month) for extended-release injectable suspension |
|
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of children 2 years of age and older with central precocious puberty (CPP). |
Initial: 1 year Renewal: 1 year |
Practitioner exemptions
- Pediatric endocrinologists are not required to submit a Special Authority request for coverage
Special notes
- Eligard is not available for Plan G coverage
- For any cancer-related condition, please contact the BC Cancer Agency at 604-877-6098 ext. 4610